Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.
|There are currently no events scheduled.|
|American Stock Transfer and Trust Company|
59 Maiden Lane
New York, NY 10038
Phone: (800) 937-5449
Fax: (718) 236-4588
|Gross Hartman LLC|
1877 Broadway, Suite 601
Boulder, CO 80302
Phone: (303) 926-4823
707 Seventeenth Street, Suite 2700
Denver, CO 80202
Phone: (303) 295-5572
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.